Jubilant Ingrevia Ltd
Jubilant Ingrevia Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Specialty Chemicals and Nutrition segments expected to sustain strong growth; these now contribute ~63% of revenue and 90% of EBITDA. Specialty and Nutrition segments contribute ~63% of revenue and ~90% of EBITDA, expected to sustain strong growth and margin expansion.
From Jubilant Ingrevia Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Specialty Chemicals and Nutrition segments expected to sustain strong growth; these now contribute ~63% of revenue and 90% of EBITDA.
- Anticipated 20%-25% year-on-year growth driven by specialty chemicals and export growth, offsetting feed segment volatility.
- Pharma CDMO business funnel doubled in last year; strong traction with innovators and tier-1 CDMOs in US, EU, Japan.
- CDMO agro plant capacity expansion underway; first agro contract deliveries started; big CDMO order supply expected early 2026.
- Semiconductor segment has 12+ molecules in pipeline; focus on high-value, low-volume products with expected commercial-stage progress.
- New multi-purpose plants under construction and debottlenecking ongoing to enhance capacity by 15-20%.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Jubilant Ingrevia Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Rs. 2000 crore invested recently, with 70% allocated to specialty chemicals, mainly for multipurpose and dedicated plants serving CDMO and Fine Chemicals businesses.
- Major ongoing CAPEX includes a big dedicated plant for an agro CDMO contract at Bharuch, expected to complete by end FY’26.
- Additional CAPEX projects: new boiler at Bharuch (commissioning expected Q2 FY’26), debottlenecking existing plants at Bharuch and Gajraula to increase capacity by 15-20%, and a new multi-purpose plant (MPP8) at Gajraula with construction starting soon.
- Niacinamide plant commissioned in March is being converted to a multi-purpose plant for human nutrition.
2 more points management made on capital expenditure plans
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Jubilant Ingrevia Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Jubilant Ingrevia has a robust CDMO order book with over 70 active molecules in the pipeline, representing a multi-thousand crore addressable market.
- The pharma segment funnel has doubled in the last year, engaging with over 30 key global accounts across EU, US, and Japan.
- In agro CDMO, the company has announced two contracts last year and expects 5-6 more contracts in advanced stages, with deliveries already started on the first agro CDMO order.
- A significant $300 million agro CDMO contract is in execution, with plant commissioning and supplies expected early 2026.
2 more points management made on order book & pipeline
Jubilant Ingrevia Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.2K Cr, net profit ₹86 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Jubilant Ingrevia Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q3 FY25 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
Others in Chemicals & Petrochemicals this season
- Balaji Amines Ltd (Q1 FY26)
Q1FY26 consolidated revenue from operations: ₹367 crore, up 2% quarter-on-quarter from ₹361 crore in Q4FY25, but down 7% year-on-year from ₹393 crore in Q1FY25…
- Linde India Ltd (Q1 FY26)
Net Revenue for FY ended Mar’25 was INR 24,854 million, down 10.2% (–2,833 million) YoY from INR 27,687 million. Key concall takeaways from Linde India Ltd's…
- Vidhi Specialty Food Ingredients Ltd (Q1 FY26)
87.9 Crores . Key concall takeaways from Vidhi Specialty Food Ingredients Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- Chemcon Speciality Chemicals Ltd (Q1 FY26)
Q1 FY26 revenue from operations: ₹53.5 Cr, up 18% YoY from ₹45.5 Cr in Q1 FY25 (Page 7 & 6). Key concall takeaways from Chemcon Speciality Chemicals Ltd's Q1…
Frequently Asked Questions
What were Jubilant Ingrevia Ltd Q1 FY26 results?
Specialty Chemicals and Nutrition segments expected to sustain strong growth; these now contribute ~63% of revenue and 90% of EBITDA. Specialty and Nutrition segments contribute ~63% of revenue and ~90% of EBITDA, expected to sustain strong growth and margin expansion.
What is Jubilant Ingrevia Ltd share price analysis?
Jubilant Ingrevia Ltd currently shows a neutral. The stock trades at a P/E of 36.9 with a market cap of ₹11,738 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jubilant Ingrevia Ltd planning capital expenditure?
Rs.
Keep Jubilant Ingrevia Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.